Skip to Content

Aadi Bioscience Inc AADI

Morningstar Rating
$1.76 +0.08 (4.76%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AADI is trading at a 572% premium.
Price
$1.68
Fair Value
$3.14
Uncertainty
Extreme
1-Star Price
$25.45
5-Star Price
$6.72
Economic Moat
Wddyv
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AADI is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.68
Day Range
$1.701.79
52-Week Range
$1.568.13
Bid/Ask
$1.75 / $1.76
Market Cap
$43.22 Mil
Volume/Avg
311,643 / 192,291

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1.91
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
75

Comparables

Valuation

Metric
AADI
CELC
CTIC
Price/Earnings (Normalized)
Price/Book Value
0.463.67
Price/Sales
1.9114.71
Price/Cash Flow
Price/Earnings
AADI
CELC
CTIC

Financial Strength

Metric
AADI
CELC
CTIC
Quick Ratio
4.6910.641.20
Current Ratio
5.1611.231.27
Interest Coverage
−323.04−13.89−3.20
Quick Ratio
AADI
CELC
CTIC

Profitability

Metric
AADI
CELC
CTIC
Return on Assets (Normalized)
−39.73%−40.23%−46.52%
Return on Equity (Normalized)
−47.38%−56.35%
Return on Invested Capital (Normalized)
−51.68%−44.81%−143.40%
Return on Assets
AADI
CELC
CTIC
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
MqvrjgjfDfj$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
XmnmtwtlnZhxrs$121.0 Bil
Regeneron Pharmaceuticals Inc
REGN
BsmlbrmCqflw$116.0 Bil
Moderna Inc
MRNA
ZxxkkqyNlwy$51.1 Bil
argenx SE ADR
ARGX
KyznxmxtRykz$23.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
TqzbbsbwSznbjd$21.0 Bil
BioNTech SE ADR
BNTX
QxqylcrpSjmc$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
MkkfpkkNfwnpq$15.9 Bil
United Therapeutics Corp
UTHR
KspjtbtkFkh$14.0 Bil
Incyte Corp
INCY
MwsthrykSmsmqbg$12.5 Bil

Sponsor Center